Published in:
01-12-2021 | Primary Immunodeficiency | Original Research Paper
Analysis of five cases of monogenic lupus related to primary immunodeficiency diseases
Published in: Inflammation Research | Issue 10-12/2021
Login to get accessAbstract
Objective and design
We studied five cases of PID-related monogenic lupus to explore the characteristics.
Material or subjects
Among 42 cases of PID patients between 2017–2020, 5 patients were diagnosed as PID-related monogenic lupus, including 2 males and 3 females, with age range from 2 years 3 months to 13 years old.
Treatments
DMARDs, biological agents and stem cell transplantation were used to treat different patients.
Methods
We collected the clinical observation indicators, auxiliary examination and treatment of the five patients.
Results
Patient 1 was diagnosed with monogenic lupus secondary to severe combined immunodeficiency and received prednisone and methotrexate treatment. Patient 2 was diagnosed with monogenic lupus secondary to activated phosphoinositide 3-kinase δ syndrome. Allogeneic stem cell transplantation was conducted. Patient 3 was diagnosed with monogenic lupus secondary to RAS‐associated lymphoproliferative disease. The child was treated with prednisone and rituximab. Patient 4 was diagnosed with monogenic lupus secondary to PSTPIP1-associated myeloid-related proteinaemia inflammatory syndrome. The child was given methylprednisolone, methotrexate, and infliximab. Patient 5 was diagnosed with monogenic lupus secondary to A20 haploinsufficiency. The child was treated with methylprednisolone and infliximab.
Conclusions
Multiple PIDs can lead to monogenic lupus. Different PID-related monogenic lupus has different suitable targeted drugs.